Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - PharMerica CORPex99_1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 
FORM 8-K


CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 9, 2017

PHARMERICA CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
 

 
Delaware
001-33380
87-0792558
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

1901 Campus Place
Louisville, Kentucky
 
40299
(Address of principal executive offices)
 
(Zip Code)
 
(502) 627-7000
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company             

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act         
 


Item 2.02
Results of Operations and Financial Condition.

On November 9, 2017, PharMerica Corporation (the “Company”) issued a press release announcing results of operations for the third quarter ended September 30, 2017, a copy of which is attached as Exhibit 99.1.
 
Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits

99.1
Press Release of PharMerica Corporation dated November 9, 2017.
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PHARMERICA CORPORATION
   
Date: November 9, 2017
By:
 
/s/ Robert E. Dries
     
Robert E. Dries
     
Executive Vice President and
Chief Financial Officer
 

Exhibit Index

Exhibit No.
Description
   
Press Release of PharMerica Corporation dated November 9, 2017.